Sign in to view content

Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy

Glenn J. Jaffe, MD

Video
Published 2022

Related

ARCHER II, a Phase 3 Randomized Clinical Trial of ANX007 in Patients With Dry AMD and GA: Study Design andRationale Informed by Outcomes From ARCHER
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2025
CD 46 is a Potent Complement Cofactor as Part of a Clinical Strategy for Geographic Atrophy
Thomas A. Ciulla, MD, MBA, FASRS
Updates from the Field
2026
Efficacy and Safety of Anti-High Temperature Requirement A1 aHtrA1 Fab in Geographic Atrophy GA Secondary to AMD GAllego Phase 2 Randomized Trial
David A. Eichenbaum, MD, FASRS
Annual Meeting Talks
2023

Category: AMD-Non-Neovascular

See more